ID BIOMEDICAL'S CYCLING PROBE TECHNOLOGY DNA TESTS FOR DRUG-RESISTANT BACTERIA SLATED FOR LAUNCH IN 1997; POINT-OF-CARE CPT TESTS ALSO PLANNED
This article was originally published in The Gray Sheet
ID Biomedical's Cycling Probe Technology DNA-based tests for detection of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) could be launched in the U.S. in 1997 following review and approval by FDA, the company predicts. Discussing the two tests Aug. 12 at the Medical Investments Northwest conference in Seattle, ID President and CEO Frank Holler said: "We expect to be able to bring [the tests] to the market next year."
You may also be interested in...
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.
The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.